| First Author | Yang X | Year | 2023 |
| Journal | Int Immunopharmacol | Volume | 123 |
| Pages | 110774 | PubMed ID | 37567012 |
| Mgi Jnum | J:340641 | Mgi Id | MGI:7525001 |
| Doi | 10.1016/j.intimp.2023.110774 | Citation | Yang X, et al. (2023) Disruption of Histamine-H(1)R signaling exacerbates cardiac microthrombosis after periodontal disease via TLR4/NFkappaB-p65 pathway. Int Immunopharmacol 123:110774 |
| abstractText | Periodontal disease is a chronic inflammatory disease that is highly correlated with cardiovascular disease(CVD). Histamine has been proven to participate in the pathophysiological processes of cardiovascular disease and oral inflammation. However, the role of histamine in the development of cardiac microthrombosis caused by periodontal disease has not been fully elucidated. We established a murine periodontal inflammation model by injecting lipopolysaccharide (LPS) or Porphyromonas gingivalis (P. gingivalis). In order to examine the effect of histamine/H(1)R signaling on cardiac injury after periodontal disease, we used histidine decarboxylase- knockout (HDC(-/-)) mice and histamine 1 receptor (H(1)R) antagonist. Our results demonstrated that LPS-induced periodontal inflammation significantly increased CD11b(+)Gr-1(+) neutrophils in the peripheral blood and myocardial interstitium. Histamine deficiency resulted in further increases in P. gingivalis, neutrophils, inflammatory cytokines, and cardiac microthrombosis in the myocardium of HDC(-/-) mice compared to wild-type (WT) mice. Mechanistic analysis showed that blocking H(1)R could synergistically interact with LPS, further increasing the phosphorylation of p65, exacerbating the inflammatory response of neutrophils and endothelial cell damage. Conclusively, the disruption of histamine-H(1)R signaling exacerbates cardiac microthrombosis after periodontal disease via TLR4/NFkappaB-p65 pathway. Our findings not only reveal a link between periodontal inflammation and myocardial injury but also provided some thoughts for the use of H(1)R antagonist in clinical practice. |
